Isnes, Belgium (April 29, 2014) – iSTAR Medical SA (iSTAR), a medical device company specializing in ophthalmic implants, announced today the addition of Prof. Michael Belkin, MD, to its Scientific Advisory Board (SAB). Prof. Belkin is professor emeritus of Ophthalmology at Tel-Aviv University where he is the director of the Ophthalmic Technologies Laboratory at the university’s Eye Research Institute, located at the Sheba Medical Center, Israel, and serves as senior advisor to the Singapore Eye Research Institute.
Prof. Belkin has been involved in the establishment of over 15 medical start-ups in ophthalmology and other fields. Among his noted contributions in the glaucoma surgery field is the invention of the Ex-PRESS® Glaucoma Filtration Device developed in 1998. In 2010, Israeli-based Optonol, manufacturer of the Ex-PRESS, was acquired by Alcon, the global leader in eye care, for over $160m.
Prof. Belkin was the first full-time director of the Tel Aviv University Eye Research Institute, Chairman of the Tel-Aviv University Department of Ophthalmology and President of the Israel Society of Eye and Vision Research of which he wasa co-founder. He is the author of over 200 scientific publications and holds over 20 patents, received an MA in Science from Cambridge University, England, and an MD in Medicine from the Hebrew University of Jerusalem, Israel.
“Prof Belkin brings over 40 years of experience in the study and treatment of glaucoma and understands the growing need for next-generation implant devices to improve outcomes and quality of life for patients,” said Michel Alvarez, CEO of iSTAR. “The team is very pleased to have a pioneer in the field contribute to our robust product pipeline, and we look forward to working with him.”
“Glaucoma should be considered as a surgical disease in view of the failure of drug therapy to eliminate glaucoma blindness and visual impairment even where ophthalmic care and drugs are available. A safe, simple surgery with longlasting intraocular pressure lowering effect will contribute considerably to reducing glaucoma morbidity, both in locations where ophthalmic treatment is plentiful and where it is not,” stated Prof. Michael Belkin.